KR102521039B1 - 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들 - Google Patents

표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들 Download PDF

Info

Publication number
KR102521039B1
KR102521039B1 KR1020227011416A KR20227011416A KR102521039B1 KR 102521039 B1 KR102521039 B1 KR 102521039B1 KR 1020227011416 A KR1020227011416 A KR 1020227011416A KR 20227011416 A KR20227011416 A KR 20227011416A KR 102521039 B1 KR102521039 B1 KR 102521039B1
Authority
KR
South Korea
Prior art keywords
gly gly
gly
ser
ala
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227011416A
Other languages
English (en)
Korean (ko)
Other versions
KR20220047892A (ko
Inventor
미카 아오야기-샤버
테레사 마가렛 크리스티안슨
멜리타 드보르자크-이웰
다니엘 제이. 벤트
시농 롱
조나단 레보위츠
다니엘 솔로몬 골드
Original Assignee
바이오마린 파머수티컬 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오마린 파머수티컬 인크. filed Critical 바이오마린 파머수티컬 인크.
Priority to KR1020237012007A priority Critical patent/KR20230054482A/ko
Publication of KR20220047892A publication Critical patent/KR20220047892A/ko
Application granted granted Critical
Publication of KR102521039B1 publication Critical patent/KR102521039B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020227011416A 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들 Active KR102521039B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237012007A KR20230054482A (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261730378P 2012-11-27 2012-11-27
US61/730,378 2012-11-27
US201361788968P 2013-03-15 2013-03-15
US61/788,968 2013-03-15
PCT/US2013/072287 WO2014085621A1 (en) 2012-11-27 2013-11-27 Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
KR1020217017007A KR102385392B1 (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217017007A Division KR102385392B1 (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237012007A Division KR20230054482A (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들

Publications (2)

Publication Number Publication Date
KR20220047892A KR20220047892A (ko) 2022-04-19
KR102521039B1 true KR102521039B1 (ko) 2023-04-12

Family

ID=49753532

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020157017224A Active KR102262882B1 (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들
KR1020237012007A Ceased KR20230054482A (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들
KR1020227011416A Active KR102521039B1 (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들
KR1020217017007A Active KR102385392B1 (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020157017224A Active KR102262882B1 (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들
KR1020237012007A Ceased KR20230054482A (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217017007A Active KR102385392B1 (ko) 2012-11-27 2013-11-27 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들

Country Status (26)

Country Link
US (8) US9376480B2 (enExample)
EP (2) EP2925776B1 (enExample)
JP (2) JP6831176B2 (enExample)
KR (4) KR102262882B1 (enExample)
CN (1) CN104822701B (enExample)
AR (1) AR093626A1 (enExample)
AU (1) AU2013352184B2 (enExample)
BR (1) BR112015012152B1 (enExample)
CA (1) CA2892146A1 (enExample)
CL (1) CL2015001371A1 (enExample)
CY (1) CY1122555T1 (enExample)
DK (2) DK2925776T3 (enExample)
ES (2) ES2679374T3 (enExample)
HR (2) HRP20181351T1 (enExample)
HU (2) HUE039334T2 (enExample)
IL (3) IL238824B (enExample)
LT (1) LT3115372T (enExample)
MX (2) MX377150B (enExample)
PL (2) PL2925776T3 (enExample)
PT (2) PT3115372T (enExample)
RS (1) RS58916B1 (enExample)
RU (1) RU2680581C2 (enExample)
SI (1) SI3115372T1 (enExample)
TW (2) TWI711632B (enExample)
WO (1) WO2014085621A1 (enExample)
ZA (1) ZA201503509B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110223147A1 (en) 2008-05-07 2011-09-15 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
RU2680581C2 (ru) 2012-11-27 2019-02-22 Байомарин Фармасьютикал Инк. Направленные терапевтические химерные белки лизосомальных ферментов и их применение
RU2692251C2 (ru) 2013-05-15 2019-06-24 Риджентс Оф Зэ Юниверсити Оф Миннесота Опосредованный аденоассоциированным вирусом перенос генов в центральную нервную систему
AU2015301809A1 (en) * 2014-08-11 2017-02-02 Shire Human Genetic Therapies, Inc. Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
WO2016049510A2 (en) * 2014-09-25 2016-03-31 The General Hospital Corporation Cell-based targeted delivery of pseudonomas exotoxin
US10556015B2 (en) 2014-10-24 2020-02-11 Criteo S.A. Lysosomal targeting of enzymes, and uses thereof
TWI752907B (zh) 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法
KR20180025865A (ko) 2015-07-06 2018-03-09 리제너론 파마슈티칼스 인코포레이티드 다중특이적 항원 결합 분자 및 이의 용도
JP2018538008A (ja) 2015-11-06 2018-12-27 バイオマリン ファーマシューティカル インコーポレイテッド リソソーム酵素の取り込みを中和する抗体または他の因子の検出のための細胞ベースアッセイ
IL261246B2 (en) * 2016-02-24 2023-03-01 Biomarin Pharm Inc Therapeutic fusion proteins targeting lysosomal enzymes, their formulations and their uses
WO2017181113A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
CL2016003282A1 (es) 2016-12-21 2017-08-18 Univ Chile Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington
CN110809583A (zh) 2017-06-07 2020-02-18 瑞泽恩制药公司 用于内化酶的组合物和方法
TWI835747B (zh) 2017-09-22 2024-03-21 賓州大學委員會 用於治療黏多醣病 ii 型之基因治療
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
KR20200118151A (ko) 2018-02-07 2020-10-14 리제너론 파마슈티칼스 인코포레이티드 치료 단백질 전달을 위한 방법 및 조성물
WO2019173756A1 (en) * 2018-03-09 2019-09-12 Avrobio, Inc. Compositions and methods for treating parkinson's disease
BR112020021962A2 (pt) * 2018-04-30 2021-01-26 Amicus Therapeutics, Inc. construtos para terapia gênica e métodos de uso
MX2020012350A (es) 2018-05-17 2021-01-29 Regeneron Pharma Anticuerpos anti-cd63, conjugados y usos de estos.
EP3802619A1 (en) 2018-06-08 2021-04-14 F. Hoffmann-La Roche AG Peptidic linker with reduced post-translational modification
EP3863663A2 (en) 2018-10-10 2021-08-18 Amicus Therapeutics, Inc. Disulfide bond stabilized polypeptide compositions and methods of use
AU2019381803A1 (en) * 2018-11-16 2021-06-10 AskBio Inc. Vectors comprising a nucleic acid encoding lysosomal enzymes fused to a lysosomal targeting sequence
BR112022006842A2 (pt) * 2019-10-10 2022-07-05 Amicus Therapeutics Inc Construtos de igf2 variante
WO2021133822A1 (en) 2019-12-24 2021-07-01 Juvena Therapeutics,Inc. Regenerative polypeptides and uses thereof
WO2021183895A1 (en) 2020-03-13 2021-09-16 Biomarin Pharmaceutical Inc. Treatment of fabry disease with aav gene therapy vectors
EP4359425A4 (en) 2021-06-21 2025-04-09 Juvena Therapeutics, Inc. REGENERATIVE POLYPEPTIDES AND THEIR USES
WO2022271981A2 (en) 2021-06-23 2022-12-29 Lycia Therapeutics, Inc. Bifunctional compounds containing igf-2 polypeptides
CN115975039A (zh) * 2021-10-15 2023-04-18 中山大学 重组融合抗体和抗体-药物偶联物及其用途
US20250339384A1 (en) * 2023-01-27 2025-11-06 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122042A2 (en) 2011-03-04 2012-09-13 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
AUPN674895A0 (en) 1995-11-23 1995-12-14 Women's And Children's Hospital Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
DE10035433C2 (de) 2000-07-20 2002-07-18 Tuma Wolfgang Schonende Hochanreicherung von fetalen Zellen aus pripherem Blut und Verwendung derselben
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ATE384736T1 (de) 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2003032913A2 (en) 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US7485314B2 (en) 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
EP1514106A4 (en) 2002-05-29 2007-05-09 Zystor Therapeutics Inc TARGETED THERAPEUTIC PROTEINS
CA2528591C (en) 2003-06-12 2013-01-08 Eli Lilly And Company Glp-1 analog fusion proteins
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
ES2344302T3 (es) * 2004-02-10 2010-08-24 Zystor Therapeutics , Inc. Alfa glucosidasa acida y fragmentos de la misma.
EP1869084A2 (en) 2005-03-04 2007-12-26 Biogen Idec MA Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
US20110223147A1 (en) * 2008-05-07 2011-09-15 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
US8697654B2 (en) * 2008-12-18 2014-04-15 E I Du Pont De Nemours And Company Peptide linkers for effective multivalent peptide binding
US9029530B2 (en) 2009-01-02 2015-05-12 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
EP3679942A1 (en) * 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
US20110318327A1 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
EP2585385B1 (en) 2010-06-25 2019-12-18 Amcor Rigid Plastics USA, LLC Oxygen scavenging system for a container
US9409950B2 (en) * 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
US9409958B2 (en) * 2011-03-10 2016-08-09 Novozymes, Inc. Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
RU2680581C2 (ru) 2012-11-27 2019-02-22 Байомарин Фармасьютикал Инк. Направленные терапевтические химерные белки лизосомальных ферментов и их применение

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122042A2 (en) 2011-03-04 2012-09-13 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GenBank Accession Number NP_000254 (2010.11.21.)

Also Published As

Publication number Publication date
KR20210070389A (ko) 2021-06-14
CL2015001371A1 (es) 2015-10-09
BR112015012152B1 (pt) 2023-04-25
US9845346B2 (en) 2017-12-19
US20220127326A1 (en) 2022-04-28
RU2015125491A (ru) 2017-01-10
IL272854B (en) 2021-07-29
AU2013352184A1 (en) 2015-06-04
US20140161788A1 (en) 2014-06-12
US9771408B2 (en) 2017-09-26
JP2016505539A (ja) 2016-02-25
IL262976A (en) 2018-12-31
SI3115372T1 (sl) 2019-08-30
IL262976B (en) 2020-02-27
WO2014085621A1 (en) 2014-06-05
TW201827468A (zh) 2018-08-01
AU2013352184B2 (en) 2018-05-31
US20190225666A1 (en) 2019-07-25
US20170355744A1 (en) 2017-12-14
KR20220047892A (ko) 2022-04-19
TWI711632B (zh) 2020-12-01
EP3115372A1 (en) 2017-01-11
US11254725B2 (en) 2022-02-22
PT2925776T (pt) 2018-07-30
MX2015006644A (es) 2015-08-10
KR102385392B1 (ko) 2022-04-11
CY1122555T1 (el) 2021-01-27
HK1216026A1 (en) 2016-10-07
US20160031963A1 (en) 2016-02-04
IL272854A (en) 2020-04-30
JP6831176B2 (ja) 2021-02-17
ZA201503509B (en) 2016-11-30
IL238824B (en) 2018-11-29
HUE039334T2 (hu) 2018-12-28
EP2925776A1 (en) 2015-10-07
DK2925776T3 (en) 2018-09-03
US10301369B2 (en) 2019-05-28
DK3115372T3 (da) 2019-06-11
HUE043679T2 (hu) 2019-09-30
CN104822701A (zh) 2015-08-05
RU2680581C2 (ru) 2019-02-22
RS58916B1 (sr) 2019-08-30
HRP20190918T1 (hr) 2019-09-20
US9834587B2 (en) 2017-12-05
MX367024B (es) 2019-08-02
BR112015012152A2 (pt) 2017-08-15
EP2925776B1 (en) 2018-05-30
CN104822701B (zh) 2018-09-21
AR093626A1 (es) 2015-06-17
MX2019009191A (es) 2019-10-09
CA2892146A1 (en) 2014-06-05
HRP20181351T1 (hr) 2018-11-02
US20160039900A1 (en) 2016-02-11
US20160031964A1 (en) 2016-02-04
ES2679374T3 (es) 2018-08-24
US20160031965A1 (en) 2016-02-04
ES2729997T3 (es) 2019-11-07
TW201431884A (zh) 2014-08-16
JP6913719B2 (ja) 2021-08-04
TWI626250B (zh) 2018-06-11
MX377150B (es) 2025-03-07
KR20150088317A (ko) 2015-07-31
PL3115372T3 (pl) 2019-09-30
KR102262882B1 (ko) 2021-06-10
EP3115372B1 (en) 2019-03-06
LT3115372T (lt) 2019-06-25
PT3115372T (pt) 2019-06-12
PL2925776T3 (pl) 2018-11-30
US9376480B2 (en) 2016-06-28
US9834588B2 (en) 2017-12-05
IL238824A0 (en) 2015-06-30
JP2019206556A (ja) 2019-12-05
KR20230054482A (ko) 2023-04-24

Similar Documents

Publication Publication Date Title
KR102521039B1 (ko) 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들
US20250388644A1 (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
HK1232896A1 (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
HK1232896B (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
HK1216026B (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601